DOAC in COVID-19: Yes or No?

DOAC in COVID-19: Yes or No?

Bibliographic Details
Main Author:	Roger E. Schutgens
Format:	Article
Language:	English
Published:	Wolters Kluwer 2021-01-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/HS9.0000000000000526

Similar Items

DOACs: life-changing technologies
by: E. P. Panchenko, et al.
Published: (2020-09-01)

Evaluation of the DOAC-Stop® Procedure to Overcome the Effect of DOACs on Several Thrombophilia Screening Tests
by: Julien Favresse, et al.
Published: (2018-04-01)

Bariatric Surgery can Lower the Efficacy of DOACs
by: Zouheir Ibrahim Bitar, et al.
Published: (2020-09-01)

Laboratory Monitoring of Direct Oral Anticoagulants (DOACs)
by: Claire Dunois
Published: (2021-04-01)

D-dimer in COVID-19: A Guide With Pitfalls
by: Roger E. Schutgens
Published: (2020-08-01)

New Direct Oral Anticoagulants (DOAC) and Their Use Today
by: Heike Schwarb, et al.
Published: (2016-03-01)

Scavenging effect of DOAC-Stop on zifaxaban in vitro and in vivo
by: ZHANG Sipei, et al.
Published: (2021-07-01)

Hemodialysis in COVID-19 Patients: Yes or No? A Commentary
by: Amin Hosseini, et al.
Published: (2020-07-01)

Perioperative Management of Direct Oral Anticoagulants (DOACs): A Systemic Review
by: Tagore Sunkara, et al.
Published: (2016-12-01)

Efficacy and Safety of Direct-Acting Oral Anticoagulants (DOACs) in the Overweight and Obese
by: Kimberley Doucette, et al.
Published: (2020-01-01)

Performance Characteristics of DOAC Dipstick in Determining Direct Oral Anticoagulants in Urine
by: Job Harenberg MD, et al.
Published: (2021-03-01)

Using direct anticoagulants (DOACs) in cancer and other high-risk populations
by: Cristina Vârlan, et al.
Published: (2016-12-01)

Novel reversal agents and laboratory evaluation for direct-acting oral anticoagulants (DOAC): An update
by: Shagun B Shah, et al.
Published: (2019-01-01)

Differential benefit risk assessment of DOACs in the treatment of venous thromboembolism: focus on dabigatran
by: Leung TS, et al.
Published: (2015-07-01)

The impact of prothrombin complex concentrates when treating DOAC-associated bleeding: a review
by: Maureane Hoffman, et al.
Published: (2018-12-01)

Appropriateness of DOAC Prescribing Before and During Hospital Admission and Analysis of Determinants for Inappropriate Prescribing
by: Souad Moudallel, et al.
Published: (2018-10-01)

Rivaroxaban induced retro peritoneal hematoma: a rare complication of direct oral anticoagulants (DOACs)
by: Bouaiyda Ayoub, et al.
Published: (2020-07-01)

Could DOAC Be a Better Choice Than Warfarin in Low Compliance Patients with Fontan Procedure?
by: Jisoo Park, et al.
Published: (2021-05-01)

DOAC‐Stop in lupus anticoagulant testing: Direct oral anticoagulant interference removed in most samples
by: Steven Andrew Baker, et al.
Published: (2021-02-01)

Adrenal hemorrhage following direct oral anticoagulant (DOAC) therapy: two case reports and literature review
by: Hadaegh, F., et al.
Published: (2022)

STEM crisis or STEM surplus? Yes and yes
by: Larson, Richard, et al.
Published: (2018)

Yes, Probably
by: Richards, Hannah E B
Published: (2011)

“YES it’s the Perfect Time to Quit”: Fueling Tobacco Cessation in India during COVID-19 Pandemic
by: Shekhar Grover, et al.
Published: (2020-09-01)

Evaluation of the DOAC-Stop Procedure by LC-MS/MS Assays for Determining the Residual Activity of Dabigatran, Rivaroxaban, and Apixaban
by: L. Slavik, et al.
Published: (2019-09-01)

Getting to Yes

Screendance: Yes, And…
by: Karen Pearlman
Published: (2013-01-01)

Interrelations, yes but…
by: Véronique Sorano-Stedman
Published: (2015-03-01)

Intonation, yes and no
by: Daniel Goodhue, et al.
Published: (2018-01-01)

Yes Please
by: Braun, Justin Farris
Published: (2009)

Yes, nós temos Pasteur Yes, we have Pasteur
by: André Felipe Cândido da Silva
Published: (2009-09-01)

Prothrombin complex concentrates for DOAC‐associated bleeding, global coagulation assays, and assessments of clinical hemostasis: How to gauge the impact?
by: Joseph R. Shaw, et al.
Published: (2020-07-01)

New Insights into the Pros and Cons of the Clinical Use of Vitamin K Antagonists (VKAs) Versus Direct Oral Anticoagulants (DOACs)
by: Rick H. van Gorp, et al.
Published: (2015-11-01)

A Diagnostic Solution for Lupus Anticoagulant Testing in Patients Taking Direct Oral FXa Inhibitors Using DOAC Filter
by: Carine Farkh, et al.
Published: (2021-05-01)

‘YES YES HEAD TREMOR’ case developing after cerebellar infarction
by: Uygar Utku, et al.
Published: (2015-12-01)

Antiphospholipid Syndrome Committee of the Brazilian Society of Rheumatology position statement on the use of direct oral anticoagulants (DOACs) in antiphospholipid syndrome (APS)
by: Gustavo Guimarães Moreira Balbi, et al.
Published: (2020-05-01)

Yes, In God's Backyard
by: Cooper, Collin M.
Published: (2021)

Utopia? Yes, please!
by: Joanna Bednarek
Published: (2011-01-01)

VITAMINS FOR CHILDREN: YES OR NO?
by: O.A. Gromova
Published: (2009-08-01)

Yes- mind the gap!
by: Uwe Hamsen, et al.
Published: (2021-02-01)

Telemedicine Yes, But No Telepathy
by: Manuel Lorenzo López Reboiro, et al.
Published: (2020-09-01)